New Drug Application (NDA)
Drafts an eCTD-compliant NDA demonstrating safety and efficacy for FDA submission under 21 CFR Part 314.
Prerequisites
- Clinical trial data — Phase 1–3 protocols, CSRs, statistical analyses, patient demographics
- CMC documentation — drug substance characterization, manufacturing process, batch records, stability data
- Nonclinical study reports — pharmacology, toxicology (general, genetic, reproductive, carcinogenicity), safety pharmacology
- PK/bioavailability data — human PK, special populations, DDI studies, exposure-response analyses
- Regulatory correspondence — pre-IND/pre-NDA meeting minutes, special protocol assessments, FDA feedback
- Proposed labeling drafts — if available
- Patent and exclusivity information — patent numbers, expiration dates, exclusivity claims
Output Structure
Module 1: Administrative Information
| Element |
Requirements |
| Cover letter |
Sponsor details, application type, regulatory pathway, special designations (breakthrough, fast track, priority review, orphan) |
| FDA Form 356h |
User fee info, debarment certification, field copy designations |
| Proposed names |
Proprietary and established names |
| Indication statement |
Precise medical terminology, dosage form, route, strength(s) |
| Regulatory strategy |
Reference pre-submission meetings, SPAs, unmet medical need narrative |
Module 2: Summaries
2.5 Integrated Summary & Benefit-Risk
- Pharmacological class, MOA, therapeutic rationale
- Development program overview (nonclinical → Phase 1 → 2 → 3 logic)
- Pivotal trial summaries: design, population, endpoints, results (point estimates, CIs, p-values)
- Integrated safety: AE profile across program, SAEs, deaths, safety signals
- Risk mitigation: labeling, REMS if applicable
- Benefit-risk weighing per 21 CFR 314.50(c): efficacy magnitude vs. AE frequency/severity, disease seriousness, existing therapies
2.3 Quality Overall Summary (CMC)
| Area |
Key Elements |
| Drug substance |
Chemical name, structure (stereochemistry), MW, solubility, polymorphism, particle size |
| Synthetic pathway |
Starting materials, reagents, CPPs, in-process controls, impurity profile with qualification |
| Drug product |
Quantitative formulation, excipient justification, compatibility evidence |
| Manufacturing |
Flow diagrams, equipment specs, CPP ranges, process validation (≥3 batches) |
| Analytical methods |
Validated for identity, assay, impurities, dissolution, CU |
| Stability |
ICH Q1A (long-term, intermediate, accelerated), stability-indicating methods, trending |
| Container closure |
System compatibility; device components if applicable (specs, human factors) |
| Compliance |
21 CFR Parts 210/211 (cGMP) |
2.4 Nonclinical Overview
| Study Type |
Key Elements |
| Primary pharmacodynamics |
In vitro binding/functional assays, in vivo disease models |
| Secondary pharmacodynamics |
Off-target activity screen |
| Safety pharmacology |
hERG, in vivo QT, respiratory, CNS |
| PK (animal) |
ADME across tox species, metabolite ID, cross-species comparison |
| Acute toxicity |
Dose-response, target organ ID |
| Repeat-dose toxicity |
Duration matching intended clinical use, recovery data |
| Genetic toxicology |
Ames, in vitro chromosomal aberration, in vivo micronucleus |
| Carcinogenicity |
Two species (if chronic use), adequate duration/power |
| Reproductive toxicity |
Fertility, embryo-fetal (two species), pre/postnatal development |
All studies GLP-compliant per ICH M3(R2). Bridge nonclinical findings to clinical: starting dose selection, monitoring parameters, contraindications.
2.7 Clinical Summary
Pharmacokinetics: ADME profile — absorption (food effect, bioavailability), distribution (Vd, protein binding), metabolism (CYP isoforms, DDI potential), elimination (clearance, t½). Special populations: renal (mild→ESRD), hepatic (Child-Pugh A/B/C), elderly, pediatric, pharmacogenomics. Bioequivalence bridging if formulation changed. Exposure-response analysis → dosing justification.
Clinical Efficacy: Phase 1 (safety, PK, dose range) → Phase 2 (dose-ranging, dose selection rationale) → Phase 3 pivotal trials. For each pivotal trial: design/randomization/blinding, population (I/E criteria), primary + secondary endpoints, statistical plan (sample size, missing data, multiplicity), results with CIs and p-values, clinical meaningfulness. Include cross-trial consistency, subgroup analyses (age, sex, race, severity), and failed/negative trial explanations. Follow ICH E3 for CSR format.
Integrated Safety: Database size (total exposed, patient-years) vs. FDA adequacy guidance. Common AEs by SOC/PT (MedDRA) with dose-response. SAE narratives with causality. Death narratives (investigator + sponsor causality). Discontinuation rates. Lab shifts, vitals, ECG/QTc. Class-specific topics: hepatotoxicity (Hy's Law), immunogenicity (ADA), hypersensitivity, CV events, malignancies. Signal detection via disproportionality analysis.
Proposed Labeling (Module 1)
Draft per Physician Labeling Rule (21 CFR 201.56–57):
| Section |
Key Requirements |
| Highlights |
≤½ page; recent changes, indication, dosing, contraindications, warnings, AEs |
| Indications & Usage |
Precise population, condition, limitations |
| Dosage & Administration |
Dose selection, preparation, technique, adjustments |
| Contraindications |
Evidence-based; clear statements |
| Warnings & Precautions |
By clinical importance; boxed warning if warranted |
| Adverse Reactions |
Table format (incidence), SAE detail, discontinuation AEs |
| Drug Interactions |
Clinically significant; management recommendations |
| Specific Populations |
Pregnancy (registry if applicable), lactation, pediatric, geriatric |
| Clinical Pharmacology |
MOA, PK summary |
| Clinical Studies |
Designs + results supporting indication |
Include Medication Guide if serious public health concern; Instructions for Use if device component or complex administration.
Risk Management, Patent & Exclusivity, Environmental
- REMS (if applicable): goals, ETASU, implementation system, assessment timetable
- Patent: numbers, expiration dates, certifications; exclusivity claims (NCE 5 yr, orphan 7 yr, pediatric 6 mo)
- Environmental: claim categorical exclusion under 21 CFR 25.31; calculate EIC (max daily dose × annual patient population → aquatic concentration < 1 ppb); full EA if threshold exceeded
eCTD Assembly Checklist
Guidelines
- Trace conclusions to source data — never assert efficacy or safety without citing specific trial results or study findings
- Anticipate FDA questions — proactively address data limitations, alternative interpretations, ambiguous precedents
- Statistical rigor — include point estimates, CIs, p-values; distinguish statistical from clinical significance
- Mark gaps explicitly — flag missing data with
[DATA NEEDED: description]
- Regulatory citations [VERIFY current versions]: 21 CFR Part 314, 21 CFR Parts 210/211, 21 CFR 201.56–57, 21 CFR 25.31/25.40, ICH Q1A, ICH E3, ICH M3(R2)
- U.S. FDA jurisdiction only — do not extrapolate to EMA, PMDA, or other authorities unless instructed
- Draft for sponsor review — mark areas requiring sponsor input, additional data, or strategic decisions before submission
1---2name: nda-drug-application3description: Drafts an eCTD-compliant New Drug Application (NDA) for FDA submission under 21 CFR Part 314. Compiles clinical trial data, CMC documentation, nonclinical studies, pharmacokinetics, integrated safety analyses, and proposed labeling into five-module eCTD structure. Use when preparing an NDA, FDA drug approval submission, pharmaceutical regulatory filing, or eCTD assembly for a new molecular entity.4---5
6# New Drug Application (NDA)
7
8Drafts an eCTD-compliant NDA demonstrating safety and efficacy for FDA submission under 21 CFR Part 314.
9
10## Prerequisites
11
121. **Clinical trial data** — Phase 1–3 protocols, CSRs, statistical analyses, patient demographics
132. **CMC documentation** — drug substance characterization, manufacturing process, batch records, stability data
143. **Nonclinical study reports** — pharmacology, toxicology (general, genetic, reproductive, carcinogenicity), safety pharmacology
154. **PK/bioavailability data** — human PK, special populations, DDI studies, exposure-response analyses
165. **Regulatory correspondence** — pre-IND/pre-NDA meeting minutes, special protocol assessments, FDA feedback
176. **Proposed labeling drafts** — if available
187. **Patent and exclusivity information** — patent numbers, expiration dates, exclusivity claims
19
20## Output Structure
21
22### Module 1: Administrative Information
23
24| Element | Requirements |
25|---|---|
26| Cover letter | Sponsor details, application type, regulatory pathway, special designations (breakthrough, fast track, priority review, orphan) |
27| FDA Form 356h | User fee info, debarment certification, field copy designations |
28| Proposed names | Proprietary and established names |
29| Indication statement | Precise medical terminology, dosage form, route, strength(s) |
30| Regulatory strategy | Reference pre-submission meetings, SPAs, unmet medical need narrative |
31
32### Module 2: Summaries
33
34#### 2.5 Integrated Summary & Benefit-Risk
35
36- Pharmacological class, MOA, therapeutic rationale
37- Development program overview (nonclinical → Phase 1 → 2 → 3 logic)
38- Pivotal trial summaries: design, population, endpoints, results (point estimates, CIs, p-values)
39- Integrated safety: AE profile across program, SAEs, deaths, safety signals
40- Risk mitigation: labeling, REMS if applicable
41- Benefit-risk weighing per 21 CFR 314.50(c): efficacy magnitude vs. AE frequency/severity, disease seriousness, existing therapies
42
43#### 2.3 Quality Overall Summary (CMC)
44
45| Area | Key Elements |
46|---|---|
47| Drug substance | Chemical name, structure (stereochemistry), MW, solubility, polymorphism, particle size |
48| Synthetic pathway | Starting materials, reagents, CPPs, in-process controls, impurity profile with qualification |
49| Drug product | Quantitative formulation, excipient justification, compatibility evidence |
50| Manufacturing | Flow diagrams, equipment specs, CPP ranges, process validation (≥3 batches) |
51| Analytical methods | Validated for identity, assay, impurities, dissolution, CU |
52| Stability | ICH Q1A (long-term, intermediate, accelerated), stability-indicating methods, trending |
53| Container closure | System compatibility; device components if applicable (specs, human factors) |
54| Compliance | 21 CFR Parts 210/211 (cGMP) |
55
56#### 2.4 Nonclinical Overview
57
58| Study Type | Key Elements |
59|---|---|
60| Primary pharmacodynamics | In vitro binding/functional assays, in vivo disease models |
61| Secondary pharmacodynamics | Off-target activity screen |
62| Safety pharmacology | hERG, in vivo QT, respiratory, CNS |
63| PK (animal) | ADME across tox species, metabolite ID, cross-species comparison |
64| Acute toxicity | Dose-response, target organ ID |
65| Repeat-dose toxicity | Duration matching intended clinical use, recovery data |
66| Genetic toxicology | Ames, in vitro chromosomal aberration, in vivo micronucleus |
67| Carcinogenicity | Two species (if chronic use), adequate duration/power |
68| Reproductive toxicity | Fertility, embryo-fetal (two species), pre/postnatal development |
69
70All studies GLP-compliant per ICH M3(R2). Bridge nonclinical findings to clinical: starting dose selection, monitoring parameters, contraindications.
71
72#### 2.7 Clinical Summary
73
74**Pharmacokinetics:** ADME profile — absorption (food effect, bioavailability), distribution (Vd, protein binding), metabolism (CYP isoforms, DDI potential), elimination (clearance, t½). Special populations: renal (mild→ESRD), hepatic (Child-Pugh A/B/C), elderly, pediatric, pharmacogenomics. Bioequivalence bridging if formulation changed. Exposure-response analysis → dosing justification.
75
76**Clinical Efficacy:** Phase 1 (safety, PK, dose range) → Phase 2 (dose-ranging, dose selection rationale) → Phase 3 pivotal trials. For each pivotal trial: design/randomization/blinding, population (I/E criteria), primary + secondary endpoints, statistical plan (sample size, missing data, multiplicity), results with CIs and p-values, clinical meaningfulness. Include cross-trial consistency, subgroup analyses (age, sex, race, severity), and failed/negative trial explanations. Follow ICH E3 for CSR format.
77
78**Integrated Safety:** Database size (total exposed, patient-years) vs. FDA adequacy guidance. Common AEs by SOC/PT (MedDRA) with dose-response. SAE narratives with causality. Death narratives (investigator + sponsor causality). Discontinuation rates. Lab shifts, vitals, ECG/QTc. Class-specific topics: hepatotoxicity (Hy's Law), immunogenicity (ADA), hypersensitivity, CV events, malignancies. Signal detection via disproportionality analysis.
79
80### Proposed Labeling (Module 1)
81
82Draft per Physician Labeling Rule (21 CFR 201.56–57):
83
84| Section | Key Requirements |
85|---|---|
86| Highlights | ≤½ page; recent changes, indication, dosing, contraindications, warnings, AEs |
87| Indications & Usage | Precise population, condition, limitations |
88| Dosage & Administration | Dose selection, preparation, technique, adjustments |
89| Contraindications | Evidence-based; clear statements |
90| Warnings & Precautions | By clinical importance; boxed warning if warranted |
91| Adverse Reactions | Table format (incidence), SAE detail, discontinuation AEs |
92| Drug Interactions | Clinically significant; management recommendations |
93| Specific Populations | Pregnancy (registry if applicable), lactation, pediatric, geriatric |
94| Clinical Pharmacology | MOA, PK summary |
95| Clinical Studies | Designs + results supporting indication |
96
97Include Medication Guide if serious public health concern; Instructions for Use if device component or complex administration.
98
99### Risk Management, Patent & Exclusivity, Environmental
100
101- **REMS** (if applicable): goals, ETASU, implementation system, assessment timetable
102- **Patent**: numbers, expiration dates, certifications; exclusivity claims (NCE 5 yr, orphan 7 yr, pediatric 6 mo)
103- **Environmental**: claim categorical exclusion under 21 CFR 25.31; calculate EIC (max daily dose × annual patient population → aquatic concentration < 1 ppb); full EA if threshold exceeded
104
105## eCTD Assembly Checklist
106
107- [ ] Module 1: Administrative, labeling, patent info
108- [ ] Module 2: Summaries (quality, nonclinical, clinical)
109- [ ] Module 3: Quality (CMC) full data
110- [ ] Module 4: Nonclinical study reports
111- [ ] Module 5: Clinical study reports
112- [ ] Cross-references and hyperlinks between modules
113- [ ] Consistent terminology throughout
114- [ ] Proper eCTD file naming and metadata
115- [ ] Gap analysis: flag missing data and strategic decision points
116
117## Guidelines
118
1191. **Trace conclusions to source data** — never assert efficacy or safety without citing specific trial results or study findings
1202. **Anticipate FDA questions** — proactively address data limitations, alternative interpretations, ambiguous precedents
1213. **Statistical rigor** — include point estimates, CIs, p-values; distinguish statistical from clinical significance
1224. **Mark gaps explicitly** — flag missing data with `[DATA NEEDED: description]`
1235. **Regulatory citations** [VERIFY current versions]: 21 CFR Part 314, 21 CFR Parts 210/211, 21 CFR 201.56–57, 21 CFR 25.31/25.40, ICH Q1A, ICH E3, ICH M3(R2)
1246. **U.S. FDA jurisdiction only** — do not extrapolate to EMA, PMDA, or other authorities unless instructed
1257. **Draft for sponsor review** — mark areas requiring sponsor input, additional data, or strategic decisions before submission
CaseMark